Meta-analysis of efficacy and safety of combination treatment with angiogenesis inhibitors for platinum-sensitive recurrent ovarian cancer
Objective To investigate the efficacy and safety of angiogenesis inhibitors combined with standard chemotherapy or poly(ADP-ribose)polymerase(PARP)inhibitors in the treatment of platinum-sensitive recurrent ovarian cancer.Methods The Embase,PubMed,the Cochrane Library and ClinicalTrial.gov databases were searched to screen randomized controlled trial(RCT)on angiogenesis inhibitors combined with chemotherapy or PARP inhibitors in the treatment of platinum-sensitive recurrent ovarian cancer(experimental group)and chemotherapy or PARP inhibitors alone(control group)from January 1,2011 to December 8,2023.After extracting data and evaluating publication bias,Meta-analysis was performed using R language.Results A total of 5 RCT studies involving 1 936 patients with platinum-sensitive recurrent ovarian cancer were included.The progression-free survival(PFS)and overall survival(OS)of the experimental group were longer than those of the control group,and the differences were statistically significant(P<0.05);the PFS and OS of the two regimens with different mechanisms of action improved,but there were no significant differences in the outcome of PFS and OS(P>0.05);there were no significant differences in PFS and OS between angiogenesis inhibitors combined with PARP inhibitors or not(P>0.05).The incidence of serious adverse reactions in the experimental group was higher than that in the control group,and the difference was statistically significant(P<0.05);the incidences of proteinuria,hypertension and thrombosis in the experimental group were higher than those in the control group,and the differences were statistically significant(P<0.05).The adverse reactions of grade≥3 were analyzed,the results showed that the incidences of proteinuria,hypertension,decreased platelet count,diarrhea and fatigue in the experimental group were higher than those in the control group(P<0.05).Conclusion The combined treatment with angiogenesis inhibitors can prolong OS and PFS in patients with platinum-sensitive recurrent ovarian cancer,but it also increases the incidences of some adverse reactions.The number of literatures included in this study is limited,so more related experiments are needed to test.
angiogenesis inhibitorcombination treatmentplatinum-sensitive recurrent ovarian cancer
NETL
NSTL
万方数据
